The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.
Just as genes contribute to whether you will be tall or short, black-haired or blond, your genes also determine how you will respond to medicines. Genes are like recipes—they carry instructions for making protein molecules. As medicines travel through your body, they interact with thousands of proteins. Small differences in the composition or quantities of these molecules can affect how medicines do their jobs.
These differences can be due to diet, level of activity, or the medicines a person takes, but they can also be due to differences in genes. By understanding the genetic basis of drug responses, scientists hope to enable doctors to prescribe the drugs and doses best suited for each individual.
The University of Maryland Medical Center is now offering a simple genetic test to patients who receive heart stents to determine whether they have a genetic deficiency that affects how they respond to a common drug to prevent blood clots.
Hamilton Storage is proud to introduce the new SAM HD, a low-capacity automated sample management system. SAM HD is the reliable, walkaway solution for labs seeking to transition from manual to automated sample storage.
Individualized medicine is no longer the lore of science fiction. It is offering new hope for patients with cancer, heart disease, depression and rare diseases for which there historically have been no diagnosis or treatment. And that's just the beginning.
Illumina sees a widespread demand for genotyping products and a continued relevance of arrays in human disease and translational research.
SCIENTISTS at the University of Huddersfield led by Dr Patrick McHugh have embarked on a project that could lead to a more effective treatment for depression.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
Firstly, a sample must be transported from the clinic to the laboratory. Simple tests may be undertaken in a small lab within the hospital or clinic, whilst complex testing such as drug susceptibility testing is often done in a large centralized laboratory many miles from the clinic
Illumina, Inc. today announced that it has signed deals with 12 customers for its new Infinium Global Screening Array (GSA).
As individuals and as populations our risks of getting diseases are determined partly genetically and partly from the environment that we live in. An important part of that environment that mediates between the outside world and the inside world of our bodies is the microbiome.
Call it personalized medicine for depression -- but the prescription in this case is exercise, which University of Florida Health researchers have found helps people with certain genetic traits.
Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients--with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions.
Federal officials with the White House and National Institutes of Health announced today that Vanderbilt University Medical Center will lead the Direct Volunteers Pilot Studies under the first grant to be awarded in the federal Precision Medicine Initiative Cohort Program.
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children's Research Hospital scientists led the study, results of which set the stage to expand the use of a patient's genetic make-up to tailor chemotherapy.
Patients who go to UPMC Presbyterian for heart catheterization and who receive a stent to treat clogged arteries are now being screened with a simple blood test to determine if they have a gene variant that makes them less likely to respond to a blood-thinning medication commonly prescribed after the procedure.
Cadavers have long been one of the most important resources for anatomy teaching in medical school. Now, they are also at the forefront of cutting-edge genetics teaching, thanks to innovative thinking by professors at the Lewis Katz School of Medicine at Temple University.
A review of medical records of patients with genetic variations linked with cardiac disorders found that patients often did not have any symptoms or signs of the conditions, questioning the validity of some genetic variations thought to be related to serious disorders, according to a study in the January 5 issue of JAMA.
The rate of growth in children varies with the season while higher latitude and greater summer daylight exposure makes a significant difference in results for children treated with growth hormone, according to new research from The University of Manchester.
How is individualized medicine working? Let us count the ways. That's just what Mayo Clinic Vice President Gianrico Farrugia, M.D., did this morning in his opening keynote at the 4th annual Individualizing Medicine Conference. The core of his talk highlighted five areas in which the knowledge and know-how from the human genome will be most impactful in patient care, not just at Mayo Clinic, but anywhere in the nation and globally.
PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.